Abeona Therapeutics Inc (NASDAQ:ABEO) Short Interest Update

Abeona Therapeutics Inc (NASDAQ:ABEO – Get Rating) was the recipient of a large growth in short interest in February. As of February 28th, there was short interest totalling 460,500 shares, a growth of 6.7% from the February 13th total of 431,600 shares. Based on an average daily trading volume, of 244,900 shares, the short-interest ratio is presently 1.9 days. Currently, 2.8% of the company’s shares are sold short.

Analyst Upgrades and Downgrades

Separately, StockNews.com assumed coverage on Abeona Therapeutics in a report on Thursday. They set a “hold” rating on the stock.

Institutional Investors Weigh In On Abeona Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Creative Planning purchased a new stake in Abeona Therapeutics in the 4th quarter valued at $62,000. Dimensional Fund Advisors LP purchased a new stake in shares of Abeona Therapeutics during the 3rd quarter valued at $103,000. Jane Street Group LLC purchased a new stake in shares of Abeona Therapeutics during the 4th quarter valued at $115,000. Renaissance Technologies LLC increased its holdings in Abeona Therapeutics by 3.1% in the 2nd quarter. Renaissance Technologies LLC now owns 2,398,166 shares of the biopharmaceutical company’s stock worth $499,000 after acquiring an additional 72,350 shares during the last quarter. Finally, State Street Corp increased its holdings in Abeona Therapeutics by 24.6% in the 2nd quarter. State Street Corp now owns 377,402 shares of the biopharmaceutical company’s stock worth $78,000 after acquiring an additional 74,600 shares during the last quarter. 37.69% of the stock is owned by hedge funds and other institutional investors.

Abeona Therapeutics Stock Down 5.9 %

Shares of ABEO opened at $2.39 on Friday. Abeona Therapeutics has a 12-month low of $2.19 and a 12-month high of $9.35. The business’s fifty day moving average is $2.59 and its 200 day moving average is $3.28. The stock has a market cap of $41.06 million, a P/E ratio of -0.14 and a beta of 1.20.

About Abeona Therapeutics

(Get Rating)

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.